About OnyvaxSciencePress ReleasesClinical TrialsCareersContact
Onyvax - oncology vaccines 

Cancer Vaccines

Onyvax' s Approach

Products in Development



Science image

Onyvax's Approach

Cell Vaccines

Onyvax is developing Cell Vaccines for the treatment of cancer, based on proprietary cell lines (cells that grow indefinitely in culture) from a range of common cancers such as those of the prostate, colon, breast and kidney. The Company has derived banks of these cell lines, which express a broad range of known cancer-specific markers (antigens), as well as many targets that have yet to be identified. This is especially important when little is known of the repertoire of markers produced by certain types of cancer, as is the case with prostate cancer. Because cancer cells also mutate rapidly, a drug or vaccine targeting only a single marker may not attack all the cells in a tumor, leading to resistance and rapid disease recurrence. Onyvax believes its Cell Vaccine approach has the potential to overcome these obstacles by correcting for both the immune deficit caused by cancer and simultaneously targeting multiple tumor markers.

Each of Onyvax's Cell Vaccines consists of a combination of multiple cell-lines that represent different stages of the particular cancer. Because there is only one vaccine formulation for each cancer type, these vaccines can be manufactured in bulk under optimized conditions. There is also increasing evidence that because the cells are not matched to the patient - and therefore viewed as foreign by the immune system - they are capable of generating a more potent immune response. During the manufacturing process the cells are inactivated so they cannot reproduce in the human body.

Onyvax's cancer therapies have been shown in clinical studies to be safe and well tolerated, especially compared with conventional therapies -- the most common side effects have been mild, transient flu-like symptoms and irritation at the injection site. Onyvax's vaccines are administered on an out-patient basis and currently designed to complement existing therapies.

Onyvax Scientific Publications (from 2004)

- click the title to open a window containing the abstract

PAPERS

Pre-treatment frequency of circulating IL-17+CD4+T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients
Evelyna Derhovanessian, Victoria Adams, Karin Hähnel, Andrea Groeger, Stephen Ward, Graham Pawelec
International Journal of Cancer. Submitted October 2008

A novel murine model of allogeneic vaccination against renal cancer.
Havranek EG, Labarthe MC, Ward S, Anderson CJ, Whelan MA, Pandha H.
BJU Int. 2008 May;101(9):1165-9.

A novel murine model of allogeneic vaccination against prostate cancer.
Labarthe MC, Theocharous P, Russell N, Todryk S, Bangma C, Thraves P, Dalgleish AG, Whelan MA.
Cancer Immunol Immunother. 2008 Apr;57(4):453-65.

Technical challenges facing therapeutic cancer vaccines.
Ward S, Copier J, Dalgleish A.
Curr Opin Drug Discov Devel. 2008 Mar;11(2):168-77

Cell based cancer vaccines: regulatory and commercial development.
Copier J, Ward S, Dalgleish A.
Vaccine. 2007 Sep 27;25 Suppl 2:B35-46.

Cancer vaccines as a therapeutic modality: The long trek.
Dalgleish AG and Whelan MA.
Cancer Immunol Immunother. 2006 Aug;55(8):1025-32.

The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model.
Labarthe MC, Halanek N, Birchall L, Russell N, Desel C, Todryk S, Peters MJ, Lucas A, Falkenberg FW, Dalgleish AG, Whelan M, Ward SJ.
Cancer Immunolology and Immunotherapy. 2006 Mar;55(3):277-88.

Delayed Disease Progression after Allogeneic Cell Vaccination in Hormone-Resistant Prostate Cancer and Correlation with Immunologic Variables
Agnieska Michael, Graham Ball, Nadine Quatan, Fatima Wushishi, Nick Russell, Joe Whelan, Prabir Chakraborty, David Leader, Michael Whelan, and Hardev Pandha.
Clin Cancer Res 2005 Jun;11(12)

Novel immunotherapeutic approaches to prostate cancer.
Dalgleish A, Whelan M.
Curr Opin Mol Ther. 2005 Feb;7(1):30-4.


JOURNAL – GUEST EDITORS

Therapeutic cancer vaccines.
Ward S, Dalgleish A.
Vaccine. 2007 Sep 27;25 Suppl 2:B1-3


POSTERS AND PRESENTATIONS

Serum free medium one of the keys to successful cytokine ELISPOT assay standardization in a multicenter trial
W. Zhang, M. Ahmad, E. Tartour, A. DeLeo, G. Gaudernack, F. Jotereau, P. Laidler, C. Baxevanis, E. Naumova, A. Line , N. Aptsuari, A. Walker R. Rees, P. V. Lehmann, S. McArdle
PIVAC (oral)
October 2008

An immune screening platform to enrich for cancer vaccine responsive HRPCa patients
V. C. Adams, G. Ball, C. Lemetre, R. Rees, S. J. Ward;
ASCO-EORTC Annual Meeting on Molecular Markers in Cancer
October 2008

Frequency of IL-17-producing CD4+ T-cells in blood correlates inversely with clinical responses to whole-cell vaccination therapy in prostate cancer
Evelyna Derhovanessian, Karin Hahnel, Andrea Groeger, Victoria Adams, Stephen Ward, Graham Pawelec
Cancer Immunology and Immunotherapy: Realizing the Promise
September 2008

Artificial Neural Network Based Algorithm For Biomolecular Interactions Modelling
Christophe Lemetre, Lee James Lancashire, Stephen Ward, Victoria Adams, Robert Rees, Graham Roy Ball
BSPR, Cambridge, UK
July 2008

Prostate Cancer Biomarkers to predict response to Immunotherapy
B. Matharoo-Ball, C. Lemetre, V. Adams, E-M Inderberg Suso, S. Ward, G. Gaudernack, G. Ball, R. Rees
HUPO, Amsterdam, Netherlands
July 2008

Frequency of IL-17-producing CD4+ T-cells in peripheral blood correlates with clinical response to whole-cell vaccination therapy in prostate cancer patients
Evelyna Derhovanessian, Karin Hähnel, Andrea Groeger, Victoria Adams, Stephen Ward, Graham Pawelec
CIMT, Mainz, Germany
May 2008

Vaccine Therapy – The Impact of the Engineering Environment on cells during processing,
McCoy, R, Ward S and Hoare M
EFB Symbiosis 2007 13th Annual Congress, Barcelona, Spain
November 2007

Vaccine Therapy – The Impact of the Engineering Environement on cells during processing: Human Cells for Prostate Cancer Therapy
McCoy, R, Ward S and Hoare M.
Bioprocess UK Annual Conference, Cardiff,
November 2007

Onyvax prostate cancer vaccine: Clinical responses and surrogate biomarkers
Adams, V., Matharoo-Ball, B., Ball, G., Rees, R., Ward, S. J.
For oral presentation CVADD, Heidelberg, Germany
October 2007

The Impact of the Engineering Environement on cells during processing,
McCoy, R, Ward S and Hoare M
Bioprocess UK Annual Conference, Edinburgh, UK
November 2006

Allogeneic Cell Therapy: The impact of the Engineering Environment on cells during processing,
McCoy, R, Ward S and Hoare M
IMRC Briefing, UCL, London, UK
October 2006




© 1998-2009 Onyvax Ltd. All Rights Reserved